Abstracts tagged "biologic drugs and randomized trials"

Abstract Number: 1864 • ACR/ARHP Annual Meeting 2018

Ixekizumab Significantly Improves Signs, Symptoms, and Spinal Inflammation of Active Ankylosing Spondylitis/Radiographic Axial Spondyloarthritis: 16-Week Results of a Phase 3 Randomized, Active and Placebo-Controlled Trial

Désirée van der Heijde¹, James Cheng-Chung Wei², Maxime Dougados³, Philip J. Mease⁴, Atul A. Deodhar⁵, Walter P. Maksymowych⁶, Filip van Den Bosch⁷, Joachim Sieper⁸, Tetsuya Tomita⁹, Robert B.M. Landewé¹⁰, Lotus Mallbris¹¹, Fangyi Zhao¹¹, David Adams¹¹, Beth Pangallo¹¹ and Hilde Carlier¹¹, ¹Leiden University Medical Centre, Leiden, Netherlands, ²Allergy/Immunology/Rheumatology, Chung Shan Med Univ Hospital, Taichung, Taiwan, ³Rheumatology Department, Cochin Hospital, AP-HP, Paris Descartes University, Paris, France, Paris, France, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵Oregon Health & Science U, Portland, OR, ⁶University of Alberta, Edmonton, AB, Canada, ⁷Ghent University Hospital, Ghent, Belgium, Ghent, Belgium, ⁸Charité University Hospital, Berlin, Germany, ⁹Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan, ¹⁰Amsterdam Rheumatology & Clinical Immunology Center and Zuyderland Medical Center, Amsterdam; Heerlen, Netherlands, ¹¹Eli Lilly and Company, Indianapolis, IN